Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Figure 1A: D presents the median serum levels of vitamins D, E, and A at M0 and M12, along with prothrombin time (PT%) as an indirect measure of vitamin K sufficiency. 25-Hydroxyvitamin D levels increased significantly (80.2 (68 to 91) → 88.5 (79 to 108) nmol/L, n = 32, p = 0.04).

Source: 3. Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Impact of a Cystic Fibrosis Specific Multivitamin Formulation on Fat-Soluble Vitamin Status and Treatment Satisfaction in Young Children

Study design awaiting verification · Children · 2025

Original publication title

Impact of a Cystic Fibrosis Specific Multivitamin Formulation on Fat-Soluble Vitamin Status and Treatment Satisfaction in Young Children

Anne Munck; Raphael Enaud; Jeanne Languepin; Natascha Remus; Nathalie Wizla; Frederique Chedevergne; Stephanie Bui; Amelie Arrouy; Marie Mittaine; Megan Quinn; Amy Wahlquist; Isabelle Sermet-Gaudelus

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Background: Children with cystic fibrosis (CwCF) are at increased risk of fat-soluble vitamin (FSV) deficiency due to fat malabsorption. In France, children were usually supplemented with multiple individual vitamin preparations but have recently converted to DEKAs Plus Liquid (DPL), an absorption-enhanced, CF-specific, multivitamin formulation that includes vitamins D3, E, K1, A (beta-carotene and retinol), B, C, zinc, and selenium. We evaluated the impact of this change on FSV levels, treatment satisfaction, and compliance. Methods: Young CwCF (n = 39, mean age 2.3 ± 1.1 years) were analyzed retrospectively.

Serum FSV levels, prothrombin time, treatment satisfaction, and compliance were assessed at baseline (M0) and after 12 months (M12). Results: Paired data analysis was performed on the 34 who completed 12 months. After 3 months, the initial daily dose was adjusted in nine cases. Median (interquartile range) serum levels of vitamin E (19.3 (17 to 27) vs. 26.3 (20 to 31) µmol/L, p = 0.0002) and 25-hydroxyvitamin D (80.2 (68 to 91) vs. 88.5 (79 to 108) nmol/L, p = 0.04) increased. Prothrombin time and vitamin A levels showed no significant change (p = 0.7, p = 0.4, respectively).

The total number of FSV deficiencies decreased from 10 to 1, vitamin D deficiency was eliminated, and vitamin K1 supplementation increased from 76% to 100% (p = 0.008). The median treatment satisfaction score (VAS1 to 10) improved from 7 (5 to 9) to 9 (9 to 10) (p = 0.0006). Patient compliance remained high (9.5 (8.5 to 10) vs. 10 (9 to 10), p = 0.4). Conclusions: Switching from individual vitamins to DPL reduced vitamin deficiencies and improved FSV levels and patient satisfaction.

Authors’ abstract

Background: Children with cystic fibrosis (CwCF) are at increased risk of fat-soluble vitamin (FSV) deficiency due to fat malabsorption. In France, children were usually supplemented with multiple individual vitamin preparations but have recently converted to DEKAs Plus Liquid (DPL), an absorption-enhanced, CF-specific, multivitamin formulation that includes vitamins D3, E, K1, A (beta-carotene and retinol), B, C, zinc, and selenium. We evaluated the impact of this change on FSV levels, treatment satisfaction, and compliance. Methods: Young CwCF (n = 39, mean age 2.3 ± 1.1 years) were analyzed retrospectively.

Serum FSV levels, prothrombin time, treatment satisfaction, and compliance were assessed at baseline (M0) and after 12 months (M12). Results: Paired data analysis was performed on the 34 who completed 12 months. After 3 months, the initial daily dose was adjusted in nine cases. Median (interquartile range) serum levels of vitamin E (19.3 (17 to 27) vs. 26.3 (20 to 31) µmol/L, p = 0.0002) and 25-hydroxyvitamin D (80.2 (68 to 91) vs. 88.5 (79 to 108) nmol/L, p = 0.04) increased. Prothrombin time and vitamin A levels showed no significant change (p = 0.7, p = 0.4, respectively).

The total number of FSV deficiencies decreased from 10 to 1, vitamin D deficiency was eliminated, and vitamin K1 supplementation increased from 76% to 100% (p = 0.008). The median treatment satisfaction score (VAS1 to 10) improved from 7 (5 to 9) to 9 (9 to 10) (p = 0.0006). Patient compliance remained high (9.5 (8.5 to 10) vs. 10 (9 to 10), p = 0.4). Conclusions: Switching from individual vitamins to DPL reduced vitamin deficiencies and improved FSV levels and patient satisfaction.

Publication and source details

Original title: Impact of a Cystic Fibrosis Specific Multivitamin Formulation on Fat-Soluble Vitamin Status and Treatment Satisfaction in Young Children

Anne Munck; Raphael Enaud; Jeanne Languepin; Natascha Remus; Nathalie Wizla; Frederique Chedevergne; Stephanie Bui; Amelie Arrouy; Marie Mittaine; Megan Quinn; Amy Wahlquist; Isabelle Sermet-Gaudelus

Children · 2025

* Correspondence: anne.munck1@gmail.com© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Alveolus Biomedical BVThis research received no external funding. The article processing charge was funded by Alveolus Biomedical BV, Platolaan 71, 3707GD Zeist, The Netherlands.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:12:43.089009+00:00

DOI: 10.3390/children12091149 · PMC12468447